N Borisow1, K Hellwig2, F Paul3,4. 1. NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Deutschland. nadja.borisow@charite.de. 2. Klinik für Neurologie, St. Josef Hospital, Ruhr Universität Bochum, Bochum, Deutschland. 3. NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Deutschland. 4. Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
Abstract
BACKGROUND: Neuromyelitis optica spectrum disorders (NMOSD) are autoimmune inflammatory diseases of the central nervous system that mainly affect women. In some of these patients NMOSD occurs during fertile age. For this reason, treating physicians may be confronted with questions concerning family planning, pregnancy and birth. OBJECTIVE: This study provides an overview on the influence of NMOSD on fertility, pregnancy complications and pregnancy outcome. The effect of pregnancy on NMOSD course and therapy options during pregnancy are discussed. MATERIAL AND METHODS: A search of the current literature was carried out using the PubMed database. RESULTS AND CONCLUSION: Animal studies have shown lower fertility rates in NMOSD; however, studies investigating fertility in NMOSD patients are lacking. Pregnancy in NMOSD patients are associated with an increase in postpartum disease activity and a higher grade of disability after pregnancy. Some studies showed higher risks of pregnancy complications e. g. spontaneous abortions and preeclampsia. With a few limitations, acute relapses during pregnancy can be treated with methylprednisolone and/or plasma exchange/immunoadsorption. Stopping or continuing immunosuppressive therapy with azathioprine or rituximab during pregnancy should be critically weighed considering previous and current disease activity. Therefore, a joint supervision by a specialized center is recommended, particularly in specific situations such as pregnancy.
BACKGROUND:Neuromyelitis optica spectrum disorders (NMOSD) are autoimmune inflammatory diseases of the central nervous system that mainly affect women. In some of these patients NMOSD occurs during fertile age. For this reason, treating physicians may be confronted with questions concerning family planning, pregnancy and birth. OBJECTIVE: This study provides an overview on the influence of NMOSD on fertility, pregnancy complications and pregnancy outcome. The effect of pregnancy on NMOSD course and therapy options during pregnancy are discussed. MATERIAL AND METHODS: A search of the current literature was carried out using the PubMed database. RESULTS AND CONCLUSION: Animal studies have shown lower fertility rates in NMOSD; however, studies investigating fertility in NMOSD patients are lacking. Pregnancy in NMOSD patients are associated with an increase in postpartum disease activity and a higher grade of disability after pregnancy. Some studies showed higher risks of pregnancy complications e. g. spontaneous abortions and preeclampsia. With a few limitations, acute relapses during pregnancy can be treated with methylprednisolone and/or plasma exchange/immunoadsorption. Stopping or continuing immunosuppressive therapy with azathioprine or rituximab during pregnancy should be critically weighed considering previous and current disease activity. Therefore, a joint supervision by a specialized center is recommended, particularly in specific situations such as pregnancy.
Authors: Sean J Pittock; Brian G Weinshenker; Claudia F Lucchinetti; Dean M Wingerchuk; John R Corboy; Vanda A Lennon Journal: Arch Neurol Date: 2006-07
Authors: Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Marius Ringelstein; Corinna Trebst; Alexander Winkelmann; Alexander Schwarz; Mathias Buttmann; Hanna Zimmermann; Joseph Kuchling; Diego Franciotta; Marco Capobianco; Eberhard Siebert; Carsten Lukas; Mirjam Korporal-Kuhnke; Jürgen Haas; Kai Fechner; Alexander U Brandt; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann Journal: J Neuroinflammation Date: 2016-09-27 Impact factor: 8.322
Authors: Jessica Coelho; Laurent Beaugerie; Jean Frédéric Colombel; Xavier Hébuterne; Eric Lerebours; Marc Lémann; Philippe Baumer; Jacques Cosnes; Arnaud Bourreille; Jean Pierre Gendre; Philippe Seksik; Antoine Blain; Etienne H Metman; Andrée Nisard; Guillaume Cadiot; Michel Veyrac; Benoît Coffin; Xavier Dray; Fabrice Carrat; Philippe Marteau Journal: Gut Date: 2010-11-29 Impact factor: 23.059
Authors: Y Nakamura; K Yoshida; S Itoh; Y Kanai; H Tsuda; H Hashimoto; N Mitsuhashi; Y Kuwabara Journal: Am J Reprod Immunol Date: 1999-05 Impact factor: 3.886
Authors: Jeffrey L Bennett; Kevin C O'Connor; Amit Bar-Or; Scott S Zamvil; Bernhard Hemmer; Thomas F Tedder; H-Christian von Büdingen; Olaf Stuve; Michael R Yeaman; Terry J Smith; Christine Stadelmann Journal: Neurol Neuroimmunol Neuroinflamm Date: 2015-05-07
Authors: Imke Metz; Tim Beißbarth; David Ellenberger; Florence Pache; Lidia Stork; Marius Ringelstein; Orhan Aktas; Sven Jarius; Brigitte Wildemann; Hassan Dihazi; Tim Friede; Wolfgang Brück; Klemens Ruprecht; Friedemann Paul Journal: Neurol Neuroimmunol Neuroinflamm Date: 2016-02-02
Authors: Nasrin Asgari; Eoin P Flanagan; Kazuo Fujihara; Ho Jin Kim; Hanne P Skejoe; Jens Wuerfel; Hiroshi Kuroda; Su Hyun Kim; Elisabeth Maillart; Romain Marignier; Sean J Pittock; Friedemann Paul; Brian G Weinshenker Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-04-21
Authors: Maria Sepúlveda; Thaís Armangué; Nuria Sola-Valls; Georgina Arrambide; José E Meca-Lallana; Celia Oreja-Guevara; Mar Mendibe; Amaya Alvarez de Arcaya; Yolanda Aladro; Bonaventura Casanova; Javier Olascoaga; Adolfo Jiménez-Huete; Mireya Fernández-Fournier; Lluis Ramió-Torrentà; Alvaro Cobo-Calvo; Montserrat Viñals; Clara de Andrés; Virginia Meca-Lallana; Angeles Cervelló; Carmen Calles; Manuel Barón Rubio; Cristina Ramo-Tello; Ana Caminero; Elvira Munteis; Alfredo R Antigüedad; Yolanda Blanco; Pablo Villoslada; Xavier Montalban; Francesc Graus; Albert Saiz Journal: Neurol Neuroimmunol Neuroinflamm Date: 2016-04-14